Hepatitis C - Teva Announces Final Approval of Ribavirin Tablets

Teva Announces Final Approval of Ribavirin Tablets
RedNova - Dec 05 1:40 PM
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Tablets, 200 mg. Shipment of this product will begin immediately.Save to My Web

Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in Japan for Expanded Use in Treating Chronic Hepatitis
[Press Release] PR Newswire via Yahoo! Finance - Dec 22 5:30 AM
Schering-Plough Corporation today announced that Schering-Plough K.K., the company's country operations in Japan, has received marketing approval for a new, additional indication for PEG-INTRON Powder for Injection in combination with REBETOL Capsules -- the treatment of chronic hepatitis C in adult patients other than those with genotype 1 virus and high viral load.Save to My Web

FDA grants final approval for Teva's Ribavirin
Globes Online - Dec 06 12:55 AM
Teva's Ribavirin tablets are the generic equivalent of Roche's Copegus tablets for chronic hepatitis C. The brand product's annual sales: $203 million.Save to My Web

MIGENIX Completes License Agreement for MX-594AN http://www.migenix.com
T-Net British Columbia - Dec 08 7:25 AM
Vancouver, BC, December 8, 2005--(T-Net)--MIGENIX Inc. and Cutanea Life Sciences, Inc. have entered into a License Agreement to develop and commercialize MX-594AN for a number of dermatological indications.Save to My Web